Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma

Israa Habeeb Naser; Muhaned Zaid; Eyhab Ali; Hayder Imad Jabar; Anfal Nabeel Mustafa; Mahmood Hasen Shuhata Alubiady; Montather F Ramadan; Khursheed Muzammil; Reem Mohsin Khalaf; Sarah Salah Jalal; Ahmed Hussien Alawadi; Ali Alsalamy

doi:10.1007/s00210-023-02885-9

Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma

Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec 14. doi: 10.1007/s00210-023-02885-9. Online ahead of print.

Authors

Affiliations

¹ Medical Laboratories Techniques Department, AL-Mustaqbal University, Hillah, Babil, Iraq.
² Department of Pharmacy, Al-Manara College for Medical Sciences, Maysan, Amarah, Iraq.
³ Al-Zahraa University for Women, Karbala, Iraq.
⁴ Department of Pharmaceutics, College of Pharmacy, University of Al-Ameed, Karbala, Iraq.
⁵ Department of Pharmacy, Al-Noor University College, Nineveh, Iraq.
⁶ Department of Pharmacy, Al-Hadi University College, Baghdad, Iraq.
⁷ College of Dentistry, Al-Ayen University, Thi-Qar, Iraq.
⁸ Department of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University, Abha, Saudi Arabia.
⁹ Department of Pharmacy, Mazaya University College, Annasiriyah, Iraq.
¹⁰ College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.
¹¹ College of Technical Engineering, the Islamic University, Najaf, Iraq.
¹² College of Technical Engineering, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
¹³ College of Technical Engineering, the Islamic University of Babylon, Babylon, Iraq.
¹⁴ College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, Iraq. shadisadegh77@gmail.com.

PMID: 38095649
DOI: 10.1007/s00210-023-02885-9

Abstract

This comprehensive review delineates the latest advancements in stimuli-responsive drug delivery systems engineered for the targeted treatment of breast carcinoma. The manuscript commences by introducing mammary carcinoma and the current therapeutic methodologies, underscoring the urgency for innovative therapeutic strategies. Subsequently, it elucidates the logic behind the employment of stimuli-responsive drug delivery systems, which promise targeted drug administration and the minimization of adverse reactions. The review proffers an in-depth analysis of diverse types of stimuli-responsive systems, including thermoresponsive, pH-responsive, and enzyme-responsive nanocarriers. The paramount importance of material choice, biocompatibility, and drug loading strategies in the design of these systems is accentuated. The review explores characterization methodologies for stimuli-responsive nanocarriers and probes preclinical evaluations of their efficacy, toxicity, pharmacokinetics, and biodistribution in mammary carcinoma models. Clinical applications of stimuli-responsive systems, ongoing clinical trials, the potential of combination therapies, and the utility of multifunctional nanocarriers for the co-delivery of assorted drugs and therapies are also discussed. The manuscript addresses the persistent challenge of drug resistance in mammary carcinoma and the potential of stimuli-responsive systems in surmounting it. Regulatory and safety considerations, including FDA guidelines and biocompatibility assessments, are outlined. The review concludes by spotlighting future trajectories and emergent technologies in stimuli-responsive drug delivery, focusing on pioneering approaches, advancements in nanotechnology, and personalized medicine considerations. This review aims to serve as a valuable compendium for researchers and clinicians interested in the development of efficacious and safe stimuli-responsive drug delivery systems for the treatment of breast carcinoma.

Keywords: Drug delivery systems; Drug resistance; Mammary carcinoma; Nanocarriers; Precision therapy; Stimuli-responsive.

Publication types

Review